Under the agreement, part of Medtronic’s reimbursement will be tied to clinical improvement measures to enhance care quality while lowering medical expenses. The outcomes-based model will affect Aetna members with type 1 and type 2 diabetes who transition to Medtronic’s insulin pump from multiple daily injections.
Some Aetna policyholders will transfer to one Medtronic insulin system, called the MiniMed 670G, which continuously self-adjusts insulin amounts based on a patient’s specific needs.
More articles on payer issues:
4 things to know about BCBSA’s 2016 community health investments
Aetna moving HQs to attract ‘younger people, innovation’
Cigna CEO: 2017 growth could involve Medicare Advantage deals
